Alaven Pharmaceutical Acquires DrNatura Line of Consumer Health Remedies
Alaven Pharmaceutical Acquires DrNatura Line of Consumer Health Remedies

December 15, 2008, Teaneck, NJ. 
DFW Capital Partners announced today that its portfolio company, Alaven Pharmaceutical, has acquired the assets of DrNatura, a leading web-based direct-to-consumer marketer of colon and digestive health products.  As part of the transaction, Alaven created a separate subsidiary, Alaven Consumer Health, to house DrNatura and Alaven’s other OTC Alaven products.

 

DrNatura markets the leading consumer colon cleansing and digestive health product line, including the Colonix™, Toxinout™ and Paranil™ product lines.  Historically, DrNatura marketed solely through internet-based searches and direct-to-consumer marketing programs.  Alaven plans to continue these channels, as well as expand the DrNatura product family to target its existing retail pharmacy relationships.

Alaven financed the transaction with senior debt from GE Capital and Fifth Third Bank.

 

About DFW Capital Partners

DFW Capital Partners is a private equity investment firm focused on lower middle-market companies.  The firm concentrates on service companies, with an emphasis on healthcare and outsourced business and industrial support services.  DFW is backed by both institutional and high-net worth individual investors, and has established a 20+ year track record of success in both building leading companies, and recognizing top-quartile returns for its investors. DFW is headquartered in Teaneck, NJ.  For more information contact Keith Pennell, General Partner, at (201) 836-6000.